Biocryst Pharmaceuticals Inc
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO ® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies.
BCRX's revenue grew at a 61.8% CAGR over the last 6 years.
Current Price
$9.19
+0.33%Biocryst Pharmaceuticals Inc (BCRX) financial data including income statement, balance sheet, and cash flow statement. This page provides a comprehensive view of Biocryst Pharmaceuticals Inc's financial performance and position as a Healthcare company.
Trailing twelve-month (TTM) revenue is $874.84M. Gross profit (TTM) is $855.76M. EBITDA is $347.65M. Earnings per share (EPS) is $1.21. The P/E ratio is 7.33. Market capitalization is $1.93B.
Free cash flow (FCF) is $344.90M. Weighted average cost of capital (WACC) is 10.00%.
Historical revenue data covers 7 years from FY19 to FY25. Net income history spans 7 years. Free cash flow and capital expenditure data spans 7 years. GoodMoat displays interactive charts for revenue, net income, FCF vs CAPEX, and cash-to-debt ratios to help investors identify financial trends.
Use Biocryst Pharmaceuticals Inc's financial data to assess the company's earnings quality, balance sheet health, and cash generation. Compare key metrics across periods to identify trends before making investment decisions with GoodMoat's valuation tools.
